Cargando…
Patient-specific and healthcare real-world costs of atrial fibrillation in individuals treated with direct oral anticoagulant agents or warfarin
BACKGROUND: Anticoagulant therapies are used to prevent atrial fibrillation-related strokes, with warfarin and direct oral anticoagulant (DOAC) the most common. In this study, we incorporate direct health care costs, drug costs, travel costs, and lost working and leisure time costs to estimate the t...
Autores principales: | Pyykönen, Mikko, Linna, Miika, Tykkyläinen, Markku, Delmelle, Eric, Laatikainen, Tiina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641166/ https://www.ncbi.nlm.nih.gov/pubmed/34856979 http://dx.doi.org/10.1186/s12913-021-07125-5 |
Ejemplares similares
-
Modeling patients’ time, travel, and monitoring costs in anticoagulation management: societal savings achievable with the shift from warfarin to direct oral anticoagulants
por: Leminen, Aapeli, et al.
Publicado: (2019) -
Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation
por: Hallinen, Taru, et al.
Publicado: (2021) -
Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients
por: Hallinen, Taru, et al.
Publicado: (2016) -
Multimorbidity transitions and the associated healthcare cost among the Finnish adult population during a two-year follow-up
por: Wikström, Katja, et al.
Publicado: (2023) -
Do the classification of areas and distance matter to the assessment results of achieving the treatment targets among type 2 diabetes patients?
por: Toivakka, Maija, et al.
Publicado: (2015)